Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
3.700
-0.015 (-0.40%)
At close: Sep 18, 2026, 4:00 PM EDT
3.710
+0.010 (0.27%)
After-hours: Sep 18, 2026, 7:30 PM EDT

Neuphoria Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
202413---
Market Cap Growth
0.19%76.94%----
Enterprise Value
04-4---
Last Close Price
3.704.377.10---

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
PS Ratio
17.0520.110.85---
PB Ratio
0.810.960.70---
P/TBV Ratio
1.181.392.40---
P/FCF Ratio
--172.83---
P/OCF Ratio
--172.83---

EV Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
EV/Sales Ratio
0.163.59----

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Debt / Equity Ratio
0.000.000.010.020.020.01
Debt / FCF Ratio
--1.93---
Net Debt / Equity Ratio
-0.81-0.81-0.74-0.70-0.53-0.58
Net Debt / EBITDA Ratio
2.382.3884.560.720.561.97
Net Debt / FCF Ratio
1.611.61-182.080.840.801.51
Asset Turnover
0.040.040.56--0.10
Quick Ratio
27.3327.333.373.334.5812.02
Current Ratio
27.8527.853.563.454.8712.46
Return on Equity (ROE)
-61.70%-61.70%-2.03%-78.44%-71.40%-41.64%
Return on Assets (ROA)
-19.66%-19.66%-1.84%-39.58%-37.41%-18.40%
Return on Capital Employed (ROCE)
-32.20%-32.20%-3.40%-74.70%-83.50%-28.40%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Earnings Yield
-67.19%-56.96%-2.77%---
FCF Yield
-61.70%-52.30%0.58%---
Buyback Yield / Dilution
-170.85%-170.85%-95.01%99.94%-8.53%-73.52%
SEC Filings: 10-K · 10-Q